Abstract |
A total of 49 patients with advanced, previously untreated non-small-cell lung cancer (NSCLC) were treated with a new antifolate, Edatrexate (10-ethyl-10-deaza- aminopterin; 10-EdAM). Patients received 80 mg/m2 weekly for 12 weeks, and responders received a further 6 cycles at 2-week intervals. Dose reductions were carried out for haematological toxicity and mucositis. Response was assessed prior to each treatment according to WHO criteria. Among the 45 evaluable patients, 6 [13.3%; 95% confidence interval (CI), 6%-26%] achieved a partial response (PR) and 9 (20%; 95% CI, 11%-34%) showed a minor response (MR; 25%-50% reduction in the sum of 2 perpendicular tumour diameters). In those receiving four or more cycles of treatment, the PR and MR rates were 17.6% and 26.4%, respectively. The resultant toxicity mainly constituted skin rash, mucositis and myelosuppression. Edatrexate is active against NSCLC and produces toxicity profile similar to that of methotrexate.
|
Authors | R L Souhami, R M Rudd, S G Spiro, R Allen, P Lamond, P G Harper |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 30
Issue 6
Pg. 465-8
( 1992)
ISSN: 0344-5704 [Print] Germany |
PMID | 1327568
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Aged
- Aminopterin
(adverse effects, analogs & derivatives, pharmacology)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Drug Administration Schedule
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Neoplasm Staging
|